About CAR-T Congress EU

CAR-T cell therapy has shown unparalleled success in hematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry.

Despite the huge successes, there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond hematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximize the potential of this ground-breaking therapy.